Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Esketamine for Prevention of Depressive Symptoms After Cytoreductive Surgery in Ovarian Cancer
NCT06624878Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in major depressive disorder (MDD) comparing Esketamine Group with Placebo Group (2 arms). Primary endpoint: Incidence of postoperative depressive symptoms after cytoreductive surgery in ovarian cancer at 3 days. Started Oct 2024; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06624878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624878.